Sintilimab plus docetaxel as second-line therapy of advanced non-small cell lung cancer without targetable mutations: a phase II efficacy and biomarker study
Yongchang Zhang(Central South University), Nong Yang(Hunan Cancer Hospital)
Cited by 19
Related Papers
The NF-κB p65/miR-23a-27a-24 cluster is a target for leukemia treatment
|Oncotarget|2015|21
Mast cells induce epithelial-to-mesenchymal transition and migration in non-small cell lung cancer through IL-8/Wnt/β-catenin pathway
|Journal of Cancer|2019|21
PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer
|Annals of Translational Medicine|2020|17